<DOC>
	<DOCNO>NCT02572596</DOCNO>
	<brief_summary>Comparing intermediate-dose CTX ( ID-CTX ) G-CSF rhTPO without peripheral blood stem cell mobilization patient multiple myeloma , try find whether rhTPO combine ID-CTX + G-CSF could improve result peripheral blood stem cell mobilization .</brief_summary>
	<brief_title>Comparing Intermediate-dose CTX+ G-CSF Plus Not rhTPO PB CD34+ Cells Mobilization MM Patients</brief_title>
	<detailed_description>The purpose study try find whether rhTPO combine ID-CTX + G-CSF could improve result peripheral blood stem cell mobilization . Comparing ID-CTX G-CSF plus rhTPO peripheral blood stem cell mobilization patient multiple myeloma . rhTPO15000U/d give day 5~7 chemotherapy stem cell collection .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Diagnosed MM fulfill International Myeloma Working Group ( IMWG ) criteria MM diagnosis Eastern Cooperative Oncology Group ( ECOG ) performance status small 2 life expectancy 6 month Age least 18 y , 70 y old No active infectious disease ; severe organ failure ( except renal failure secondary MM ) All screening procedure evaluation complete All patient provide write informed consent . 1. severe impair liver function ; HIV positive active hepatitis A , B C infection ; hepatitis B virusDNA 10^4/L ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 2.5 upper limit normal ( ULN ) 2. disease could put patient high risk , include limited unstable cardiac disease , define myocardial infarction previous 6 month , New York Heart Association ( NYHA ) class IIIIV heart failure , uncontrolled atrial fibrillation hypertension 3. severe prior thrombosisevent 4. history malignancy , unless cure 3 year 5. pregnancy , lactation disagreement take contraceptive measure 6. severe infectious disease ( uncured tuberculosis , pulmonary aspergillosis ) 7. epilepsia , dementia mental disease require treatment .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hematopoietic Stem Cell Mobilization</keyword>
	<keyword>Thrombopoietin</keyword>
</DOC>